Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
Non-critical patients, hospitalized within the previous 24 hours who tested positive for
COVID-19 and have a prior history of cardiovascular disease (CVD) and/or significant risk
factors for CVD will be treated for 28 days.